Pasithea therapeutics announces positive safety review committee (src) recommendation from its ongoing phase 1 clinical trial of pas-004 in advanced cancer

Pasithea's pas-004 phase 1 trial advances to 22mg dose with no dlts or rash, reinforcing its safety profile as a next-gen mek inhibitor for nf1 and cancer.

KTTA Ratings Summary

KTTA Quant Ranking